Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprotinin in Hospitalized COVID-19 Patients
NCT04527133Unknown
- Sponsor
- Aviron
- Start
- Jun 2020
- Primary completion
- Aug 2020
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of aprotinin in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Aviron. Primary endpoints: Time to elimination of SARS-CoV-2 virus at 10 days, Time to C-reactive protein (CRP) normalization at 10 days and 1 more. Status: unknown.
02
Drugs
aprotinin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04527133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04527133.